BCL2 and B-cell chronic lymphocytic leukemia: Small molecules that bind specifically to BCL2, relieving restraints on apoptosis in CLL cells, represent a major advancement in the treatment of CLL and have dramatically improved patient outcomes in the relapsed refractory [48, 49] and treatment naïve settings [50].